February 2024 - World School of Life Sciences IP

Charting India’s Path in the Cell and Gene Therapy Landscape

Tanu Goyal February 22, 2024

Chimeric Antigen Receptor (CAR)-T cell therapy, a groundbreaking form of immunotherapy harnessing a patient’s own T cells to combat cancer, has undergone remarkable advancements over

Loss of protection (LOP) for cell and gene therapy (CGT) products approved by the U.S. FDA

Tanu Goyal February 16, 2024

Cell and gene therapies (CGTs) are generating seismic shifts in the pharmaceutical landscape by offering disease-targeting, potentially curative solutions. In recent decades, cell and gene

Will Cosentyx®face biosimilar competition soon?

Tanu Goyal February 7, 2024

Secukinumab, an IL-17A antagonist, is marketed by Novartis under the brand name Cosentyx®. In 2023, Cosentyx® observed the sales of 5 billion dollars, inclusive of

WSLI

Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.